Home » Authors » James Etheridge

Articles by James Etheridge

Celogos Receives €2.5M For Development of Cell Therapies

March 7, 2007

By James Etheridge

No Abstract

Hybrigenics Refocuses Its Efforts On Ubiquitin-Specific Proteases

Feb. 28, 2007

By James Etheridge

Genfit Renews Collaborations With Sanofi-Aventis, Solvay

Feb. 28, 2007

By James Etheridge

Genfit Renews Collaborations With Sanofi-Aventis, Solvay

Feb. 28, 2007

By James Etheridge

Hybrigenics Refocuses Its Efforts On Ubiquitin-Specific Proteases

Feb. 28, 2007

By James Etheridge

Celogos Licenses Myoblast Tool For Stress Urinary Incontinence

Feb. 21, 2007

By James Etheridge

Celogos Licenses Myoblast Tool For Stress Urinary Incontinence

Feb. 21, 2007

By James Etheridge

Cellectis Oversubscribed IPO Completed for $27.5 M

Feb. 14, 2007

By James Etheridge

Nautilus Biotech and Wyeth Partner on Hemophilia

Feb. 14, 2007

By James Etheridge

Cellectis Oversubscribed IPO Completed for $27.5 M

Feb. 14, 2007

By James Etheridge

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 8, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...